In a cohort of 85 patients with biomechanical recurrence of prostate cancer and PSA values less than 2 ng/mL, positive findings on PET imaging with PSMA-18F DCFPyL led to treatment changes in the majority of patients who had negative findings on conventional imaging, according to new research presented at the SNMMI conference.
The use of PSMA-18F DCFPyL may be more advantageous than conventional imaging in detecting biomechanical recurrence of prostate cancer in patients with low prostate-specific antigen (PSA) values, according to new research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
For the retrospective study, researchers evaluated the use of PET PSMA-18F DCFPyL (Pylarify, Lantheus) in 85 patients (mean age of 69) who had occult prostate cancer recurrence and PSA values less than 2 ng/mL. All patients in the cohort had negative computed tomography (CT), magnetic resonance imaging (MRI), ultrasound and positron emission tomography (PET)-choline exams, according to the study authors.
At a six-month follow-up, the researchers found that PET imaging with PSMA-18F DCFPyL led to treatment changes in 75 percent of patients with positive findings (31/41).
“In PET-PSMA-positive patients, the therapeutic changes found were classified as indicating or changing the planning of salvage radiotherapy treatment and/or initiating systemic treatment with hormone therapy,” noted lead study author Pedro Jose Plana Lopez, M.D., who is affiliated with Hospital Del Mar in Barcelona, Spain, and colleagues.
The study authors noted a median PSA level of 0.08 ng/dL after treatment changes were instituted in patients with positive PET PSMA results.
(Editor’s note: For related content, see “Can an Emerging PET Radiotracer Be a Viable Alternative to Multiparametric MRI for Detecting Prostate Cancer Recurrence?,” “Utilizing AI for Quantitative Assessment of Prostate Cancer Recurrence” and “Emerging PET Radiotracer May Offer Multiple Advantages in Detecting Prostate Cancer.”)
“PET-PSMA is a powerful diagnostic tool for patients with occult biochemical recurrence with PSA < 2ng/mL,” added Lopez and colleagues.
Reference
1. Lopez PJP, Amorelli FG, Cano JSB, et al. PET/CT PSMA-18F DCFPyL promotes treatment changes in occult biochemical recurrence of prostate carcinoma even with low PSA values. Presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8-11, Toronto, Canada. Available at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm . Accessed June 9, 2024.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
Study Assesses Amyloid PET/MRI Combination in Detection of Alzheimer’s Disease
July 15th 2024Emerging research revealed that a machine learning combination of amyloid beta PET and structural MRI demonstrated an 89 percent AUC in differentiating between older healthy patients and those with Alzheimer’s disease.